Xuemei Zhang

Xuemei Zhang


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2011 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
FLFangping Li
Fangping Li
WWWenwei Wang
Wenwei Wang
MGMing Gu
Ming Gu
SGStefka Gyoneva
Stefka Gyoneva
JZJie Zhang
Jie Zhang
XZXuemei Zhang
Xuemei Zhang

25 January 2023 in Life Sciences
Verified
Journal Article
Open access
LJLan Jiang
Lan Jiang
JLJiawei Li
Jiawei Li
SRSvetlana Reilly
Svetlana Reilly
HXHong Xin
Hong Xin
NGNan Guo
Nan Guo
XZXuemei Zhang
Xuemei Zhang
The organellar Ca2+-activated K+ channels share a similar ability to transfer the alteration of Ca2+ concentration to membrane conductance of potassium. Multiple effects of Ca2+-activated K+ channels on cell metabolism and complex signaling pathways during organ development have been explored. The organellar Ca2+-activated K+ channels are able to control the ionic equilibrium and are always associated with oxidative stress in different organelles and the whole cells. Some drugs targeting Ca2+-activated K+ channels have been tested for various diseases in clinical trials. In this review, the known roles of organellar Ca2+-activated K+ channels were described, and their effects on different diseases, particularly on diabetes, cardiovascular diseases, and neuro-logical diseases were discussed. It was attempted to summarize the currently known operational modes with the involvement of organellar Ca2+-activated K+ channels. This review may assist scholars to more comprehensively understand organellar Ca2+-activated K+ channels and related diseases.

27 April 2025 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
XHXuetao Hu
Xuetao Hu
ZYZanzhe Yu
Zanzhe Yu
HZHaoran Zhu
Haoran Zhu
HCHaolin Cui
Haolin Cui
FNFengling Ning
Fengling Ning
XZXuemei Zhang
Xuemei Zhang

22 December 2006 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
XZXuemei Zhang
Xuemei Zhang
XWXi-Tao Wang
Xi-Tao Wang
HCHui Cai
Hui Cai
SLSteve W. Leung
Steve W. Leung
SGSandra E. Guggino
Sandra E. Guggino

29 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
WMWang Mengling
Wang Mengling
ZFZeng Feng
Zeng Feng
NFNing Fengling
Ning Fengling
WYWang Yinhang
Wang Yinhang
HJHe Jiaqi
He Jiaqi
XZXuemei Zhang
Xuemei Zhang
Background and aims: Renal fibrosis is the common outcome in all progressive forms of chronic kidney disease. Unfortunately, the pathogenesis of the renal fibrosis remains largely unexplored, among which metabolic reprogramming plays an extremely crucial role in the evolution of renal fibrosis. Ceria nanoparticles have strong ROS scavenging and anti-inflammatory activity. The present study aims to determine whether CeNPPEG has therapeutic value for renal fibrosis.Methods: Ceria nanoparticles and Ceria nanoparticles-PEG were synthesized according to previously reported procedures with slight modifications. For the in vivo studies, unilateral ureteral obstructive -induced kidney fibrosis was chosen. Through cellular studies, TGF-β1-induced epithelial-to-mesenchymal transition in HK-2 cells of enhanced glycolysis was initially utilized to report the associations among Ceria nanoparticles-PEG, oxidative phosphorylation, glycolysis and renal fibrosis.Results: In this study, Ceria nanoparticles were developed and the Ceria nanoparticles-PEG treatment significantly ameliorated renal fibrosis in unilateral ureteral obstructive mice as well as protected HK-2 cells from transforming growth factor beta1 -induced epithelial-to-mesenchymal transition process. Furthermore, we found that Ceria nanoparticles-PEG suppressed hexokinase 1and hexokinase 2 to block the dysregulated metabolic status, in which damaged epithelial cells take glycolytic metabolism as priority to oxidative phosphorylation, exerting the protective function in the progress of renal fibrosis.Conclusions: The application of Ceria nanoparticles-PEG in this study is attempted to provide another therapeutic option on renal fibrosis.